The sustained efficacy and safety data de-risks the upcoming PDUFA decision on December 22, 2026. Monitor the FDA advisory committee meeting (if any) and the final label for commercial potential.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $15.81entry
- T+1 · 7d ago −1.83%α −1.47% · $15.52
- T+5 · 18h ago −8.10%α −6.40% · $14.53
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Mineralys Therapeutics presented long-term data from the Transform-HTN open-label extension trial of lorundrostat at AHA 2026, showing a sustained 17.8 mmHg reduction in systolic blood pressure at 48 weeks with 56% of participants achieving blood pressure below 130 mmHg. The FDA review of lorundrostat is ongoing with a PDUFA target date of December 22, 2026, and the data strengthens the safety and efficacy profile ahead of the decision.
Key Facts
- Lorundrostat demonstrated a 17.8 mmHg reduction in AOSBP from Launch-HTN baseline to Week 48 (p<0.0001)
- 56% of participants achieved AOSBP below 130 mmHg at Week 48
- 92% of participants completed 48 weeks of follow-up; serious adverse events in 4.3% (0.3% treatment-related)
- FDA PDUFA target date for lorundrostat is December 22, 2026
- Results presented at AHA Scientific Sessions 2026 in a late-breaking oral session
Financial Impact
Positive late-stage clinical data supports potential FDA approval for a drug targeting a large hypertension market; no financial figures disclosed in the release.
Risk Factors
- FDA may issue a Complete Response Letter (CRL) on CMC or other grounds despite positive clinical data
- Commercial adoption depends on label, pricing, and competition from existing antihypertensives
- Company is pre-revenue and dependent on successful approval and launch
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3398023 |
Track record
35 reports on MLYS
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +20.97% at T+20 after the Jun 11, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 8, 20268d ago Press Release Bullish 6/10 Viewing Entry $15.81 Now $14.53 −8.10% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $15.24 Now $14.53 −4.66% settles Dec 4
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $15.99 Now $14.53 −9.13% settles Dec 2
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $18.18 Now $14.53 −20.08% settles Nov 30
- Oct 28, 202619d ago Press Release Bullish 6/10 Entry $21.38 Now $14.53 −32.04% settles Nov 25
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
- Oct 19, 202628d ago 8-K Neutral 2/10 Entry $21.58 Now $14.53 −32.67% settles Nov 17
- Oct 13, 20264w ago 144 Neutral 3/10 Entry $20.76 to $16.16 Now $14.53 −30.01% ▼ −22.16% −20.89% vs SPY
- Sep 30, 20266w ago 144 Neutral 3/10 Entry $23.72 to $21.24 Now $14.53 −38.74% ▼ −10.46% −11.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers